Mayo Clinic study reveals new drugs to treat hepatitis C in post-liver transplant patients Dec. 02, 2014 Overview Show transcript Overview Surakit Pungpapong, M.D., transplant hepatologist and associate professor of medicine at Mayo Clinic's campus in Florida, talks about his latest study — how two new oral medications, used post-liver transplant, are safe and beneficial in the treatment of Hepatitis C and require only 12 weeks of treatment instead of up to one year. Related Content Q and AUnderstanding HCV and evolving treatment guidelinesVideoAdvancements at Mayo Clinic – Hepatitis C is no longer a barrier to transplantArticleHepatitis C livers now usable for transplant into patients uninfected with hepatitis C VID-20433390 Medical Professionals Mayo Clinic Study Reveals New Drugs to Treat Hepatitis C in Post Liver Transplant Patients